<DOC>
	<DOCNO>NCT01672151</DOCNO>
	<brief_summary>The aim study evaluate efficacy rapamycin Refractory Immune Thrombocytopenic Purpura ( RITP ) explore mechanism .</brief_summary>
	<brief_title>Efficacy Rapamycin Therapy With Chronic Immune Thrombocytopenia</brief_title>
	<detailed_description>Rapamycin , immunosuppressive drug , widely use prevent allograft rejection autoimmune disease . Many study show drug contributes expansion regulatory T cell preserve highly suppressive function autoreactive T cell . Patients RITP often display decreased proportion regulatory T cell flow cytometer , therefore , investigator examine efficacy rapamycin RITP patient .</detailed_description>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Clinical diagnosis idiopathic thrombocytopenic purpura Hormone immune suppression , splenectomy invalid patient bad tolerance rapamycin platelet count &lt; 10*10E9/L treatment rapamycin</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Refractory Immune Thrombocytopenic Purpura</keyword>
	<keyword>rapamycin</keyword>
	<keyword>regulatory T cell</keyword>
</DOC>